Profile data is unavailable for this security.
About the company
PCI Biotech Holding ASA is a cancer focused biopharmaceutical company based in Norway. The Company is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotech’s product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. It is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.
- Revenue in NOK (TTM)4.69m
- Net income in NOK-20.54m
- Incorporated2007
- Employees7.00
- LocationPCI Biotech Holding ASAUllernchauseen 64OSLO 0379NorwayNOR
- Phone+47 67115400
- Fax+47 67115401
- Websitehttps://www.pcibiotech.no/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lidds AB | 0.00 | -5.94m | 7.26m | 1.00 | -- | 4.57 | -- | -- | -0.0409 | -0.0409 | 0.00 | 0.0109 | 0.00 | -- | -- | 0.00 | -99.68 | -64.76 | -119.64 | -76.72 | -- | -1,554.86 | -- | -2,637.08 | -- | -- | 0.00 | -- | -- | -- | 85.23 | -- | -65.39 | -- |
| PCI Biotech Holding ASA | 4.69m | -20.54m | 8.06m | 7.00 | -- | 0.6442 | -- | 1.72 | -0.5502 | -0.5502 | 0.1256 | 0.3353 | 0.1676 | -- | 0.896 | 669,714.30 | -73.44 | -41.44 | -92.22 | -46.61 | -- | -- | -438.10 | -897.91 | -- | -- | 0.022 | -- | 125.25 | -6.43 | 19.19 | -- | -- | -- |
| Stayble Therapeutics AB | 0.00 | -8.96m | 13.09m | 2.00 | -- | 1.45 | -- | -- | -0.168 | -0.168 | 0.00 | 0.1314 | 0.00 | -- | -- | 0.00 | -78.98 | -78.82 | -83.99 | -92.78 | -- | -- | -- | -- | -- | -- | 0.0913 | -- | -- | -- | 47.69 | -- | -- | -- |
| Fluicell AB | 2.85m | -10.50m | 13.53m | 11.00 | -- | 1.18 | -- | 4.74 | -7.18 | -7.18 | 1.95 | 7.86 | 0.1257 | -2.79 | 3.22 | 268,100.00 | -46.21 | -89.03 | -62.52 | -133.15 | 428.87 | 86.83 | -367.74 | -656.39 | 0.6057 | -- | 0.00 | -- | -44.31 | -5.66 | 41.59 | -- | 33.86 | -- |
| Respiratorius AB (publ) | 0.00 | -7.40m | 14.60m | -- | -- | 0.448 | -- | -- | -1.15 | -1.15 | 0.00 | 3.87 | 0.00 | -- | -- | -- | -22.10 | -- | -22.91 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.10 | -- | -- | -- |
| Novakand Pharma AB | 0.00 | -55.25m | 17.75m | 5.00 | -- | 0.8325 | -- | -- | -0.4283 | -0.4283 | 0.00 | 0.1653 | 0.00 | -- | -- | 0.00 | -103.07 | -54.11 | -112.87 | -63.47 | -- | 70.00 | -- | -275,694.40 | -- | -- | 0.00 | -- | -- | -- | 31.32 | -- | -- | -- |
| Gabather AB | 0.00 | -4.95m | 18.21m | 2.00 | -- | -- | -- | -- | -0.0384 | -0.0384 | 0.00 | -0.0111 | 0.00 | -- | -- | 0.00 | -209.07 | -67.13 | -- | -90.59 | -- | -- | -- | -- | -- | -76.57 | -- | -- | -- | -- | 17.84 | -- | -- | -- |
| ATTANA AB | 4.37m | -13.60m | 21.98m | 6.00 | -- | 0.6084 | -- | 5.03 | -0.0154 | -0.0154 | 0.0047 | 0.0132 | 0.1425 | -0.7611 | 1.02 | 656,600.00 | -44.37 | -37.91 | -61.34 | -48.09 | 161.16 | 189.23 | -311.34 | -305.50 | 0.6079 | -3.79 | 0.1315 | -- | -18.77 | -8.69 | 7.33 | -- | 8.51 | -- |
| Lumito AB (publ) | 86.77k | -51.17m | 24.25m | 8.00 | -- | 0.1644 | -- | 279.46 | -20.16 | -20.16 | 0.0253 | 40.27 | 0.0008 | -0.4224 | 0.0791 | 6,792.50 | -47.58 | -24.12 | -62.09 | -26.46 | 546.44 | -- | -58,966.97 | -138,894.00 | 0.2668 | -22.92 | 0.1994 | -- | -- | -- | -61.08 | -- | -30.66 | -- |
| Aptahem AB | 0.00 | -7.91m | 31.94m | -- | -- | 0.244 | -- | -- | -0.6711 | -0.6711 | 0.00 | 3.77 | 0.00 | -- | -- | -- | -11.21 | -30.70 | -11.57 | -34.24 | -- | -- | -- | -- | -- | -44.15 | 0.00 | -- | -- | -- | 22.90 | -- | 88.99 | -- |
| Guard Therapeutics Intrntnl AB (publ) | 0.00 | -126.13m | 34.35m | 5.00 | -- | 0.58 | -- | -- | -7.65 | -7.65 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -161.81 | -71.09 | -197.78 | -79.80 | -- | -- | -- | -- | -- | -1,537.69 | 0.00 | -- | -- | -- | 15.23 | -- | -- | -- |
| Strategic Partners A/S | 0.00 | -5.03m | 35.38m | 1.00 | -- | 1.30 | -- | -- | -83.43 | -83.43 | 0.00 | 433.01 | 0.00 | -- | -- | 0.00 | -18.16 | -66.13 | -19.52 | -94.41 | -- | -- | -- | -- | -- | -69.91 | 0.00 | -- | -- | -- | 98.86 | -- | -- | -- |
| Peptonic Medical AB | 16.71m | -52.14m | 35.79m | 3.00 | -- | 0.481 | -- | 2.14 | -0.0068 | -0.0068 | 0.002 | 0.0037 | 0.1994 | 0.6491 | 3.47 | 2,242,000.00 | -62.23 | -52.80 | -86.90 | -72.84 | 67.85 | 54.48 | -312.10 | -141.78 | 0.2747 | -26.44 | 0.2863 | -- | -27.55 | 43.57 | -40.95 | -- | 11.04 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Storebrand Asset Management ASas of 30 Nov 2025 | 206.19k | 0.55% |
